Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2016

Open Access 01-12-2016 | Research

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Authors: Xia Xu, Fei Deng, Mengmeng Lv, Binhui Ren, Wenwen Guo, Xiaoxiang Chen

Published in: Journal of Ovarian Research | Issue 1/2016

Login to get access

Abstract

Background

No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for IDS and the prognosis-associated factors of International Federation of Gynecology and Obstetrics stage IIIc to IV HG-SOC patients.

Methods

A total of 160 IIIc to IV stage HG-SOC patients were retrospectively analyzed. Patients with large volume ascites underwent NAC and subsequent IDS from the Jiangsu Institute of Cancer Research between 1993 and 2013. The outcome of IDS-associated factors was explored by logistic regression. To predict IDS outcome, the potential values of serum CA-125 levels and CA-125 decreasing kinetics were determined by the receiver operating characteristic curve. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test.

Results

Optimal IDS was achieved in 80.6% of HG-SOC patients who underwent NAC. Multivariate analyses revealed that ascites regression (p = 0.01), serum CA-125 level (p = 0.02), and CA-125 decreasing kinetics (p = 0.01) were independent optimal IDS predictors. CA-125 decreasing kinetics, IDS outcome, and ascites volume were independently associated with overall survival (OS) (p = 0.04, p < 0.01, p = 0.03, respectively) and progression-free survival (PFS) (p < 0.01, p < 0.01, p = 0.02, respectively). Patients who exhibited disappearance of ascites (<500 ml) had longer PFS (19.7 months vs.14.9 months) and OS (32.1 months vs. 26.0 months) than patients who exhibited residual ascites (≥500 ml). Subsets with higher CA-125 decreasing kinetics (≥2.2) had longer PFS (21.4 months vs.13.1 months) and OS (29.6 months vs.26.8 months) than counterparts (kinetics < 2.2).

Conclusions

Ascites regression and CA-125 decreasing kinetics were independently associated with surgical outcome and prognosis in advanced HG-SOC patients who underwent NAC.
Literature
1.
Hannibal CG, et al. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978–2002. Acta Obstet Gynecol Scand. 2008;87(12):1353–60.CrossRefPubMed
2.
Yang L, et al. Statistics on cancer in China: cancer registration in 2002. Eur J Cancer Prev. 2005;14(4):329–35.CrossRefPubMed
3.
4.
5.
6.
Chen X, et al. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol. 2013;44(11):2373–84.CrossRefPubMedPubMedCentral
7.
Hoskins WJ, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9. discussion 979–80.CrossRefPubMed
8.
Bristow RE, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.CrossRefPubMed
9.
Elattar A, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;8:CD007565.
10.
Vergote I, Amant F, Leunen K. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists? Gynecol Oncol. 2010;119(1):1–2.CrossRefPubMed
11.
Chi DS, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559–64.CrossRefPubMed
12.
Eltabbakh GH, et al. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95(2):377–83.CrossRefPubMed
13.
Angioli R, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128(3):579–83.CrossRefPubMed
14.
Ansquer Y, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer. 2001;91(12):2329–34.CrossRefPubMed
15.
Kuhn W, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92(10):2585–91.CrossRefPubMed
16.
Chan JK, et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol. 2003;102(1):156–61.PubMed
17.
Morice P, et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol. 2003;14(1):74–7.CrossRefPubMed
18.
Giannopoulos T, et al. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 2006;27(1):25–8.PubMed
19.
Lee SJ, et al. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006;32(1):99–106.CrossRefPubMed
20.
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6.CrossRefPubMed
21.
Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Rev Anticancer Ther. 2011;11(7):1053–67.CrossRefPubMed
22.
23.
24.
25.
Wang F, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res. 2013;6(1):14.CrossRefPubMedPubMedCentral
26.
Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.CrossRefPubMed
27.
Asada K, et al. Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: case report and review of published works. J Obstet Gynaecol Res. 2014;40(3):869–72.CrossRefPubMed
28.
Chao KC, et al. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan. Taiwan J Obstet Gynecol. 2013;52(1):81–4.CrossRefPubMed
29.
Hofstetter G, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131(1):15–20.CrossRefPubMed
30.
Jorgensen TL, et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol. 2012;127(2):367–74.CrossRefPubMed
31.
32.
Vizzielli G, et al. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy? Anticancer Res. 2015;35(5):3027–32.PubMed
33.
van Meurs HS, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013;49(15):3191–201.CrossRefPubMed
34.
Cornelis S, et al. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer. 2012;22(3):407–16.CrossRefPubMed
35.
Vergote I, et al. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J Clin Oncol. 2011;29(31):4076–8.CrossRefPubMed
36.
Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.CrossRefPubMed
37.
Birkett R, Parry-Smith W, Todd R. Raised Ca125 and ascites: Is this ovarian cancer till proven otherwise? J Obstet Gynaecol. 2016;36(4):498–9.CrossRefPubMed
38.
Zivadinovic R, et al. Ascites in ovarian carcinoma - reliability and limitations of cytological analysis. West Indian Med J. 2015;64(3):236–40.PubMed
39.
Ferriss JS, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG oncology/GOG study. Gynecol Oncol. 2015;139(1):17–22.CrossRefPubMedPubMedCentral
40.
41.
Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res. 2014;34(4):1553–61.PubMed
42.
Feldheiser A, et al. Impact of ascites on the perioperative course of patients with advanced ovarian cancer undergoing extensive cytoreduction: results of a study on 119 patients. Int J Gynecol Cancer. 2014;24(3):478–87.CrossRefPubMed
43.
Kehoe S, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.CrossRefPubMed
44.
Fagotti A, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33.CrossRefPubMed
45.
Onda T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan clinical oncology group study JCOG0602. Eur J Cancer. 2016;64:22–31.CrossRefPubMed
46.
Kang S. Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence? Lancet. 2015;386(9990):223–4.CrossRefPubMed
Metadata
Title
Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
Authors
Xia Xu
Fei Deng
Mengmeng Lv
Binhui Ren
Wenwen Guo
Xiaoxiang Chen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2016
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-016-0294-z

Other articles of this Issue 1/2016

Journal of Ovarian Research 1/2016 Go to the issue

Research

Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer

Research

Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer

Research

Application of receiver operating characteristic curve in the assessment of the value of body mass index, waist circumference and percentage of body fat in the Diagnosis of Polycystic Ovary Syndrome in childbearing women

Case report

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review

Research

L-DOPA in the hu man ovarian follicular fluid acts as an antioxidant factor on granulosa cells

Retraction Note

Retraction note: Uterine mast cell tumor: a clinical and cytohistopathological study